Autoantibodies in systemic sclerosis: Clinical interest and diagnosis approach;Autoanticorps au cours de la sclérodermie systémique : Intérêt clinique et approche diagnostique

Annales de Biologie Clinique

Volumn 67, Issue 3, 2009, Pages 273-281

  Admou, B ^a   Essaadouni, L ^b   Amal, S ^b   Arji, N ^c   Chabaa, L ^a   Aouad, R El ^c  

^a University Cadi Ayyad Faculte de Medecine et de Pharmacie de Marrakech   (Morocco)

^b CHU Mohammed VI   (Morocco)

^c INSTITUT NATIONAL D HYGIÈNE   (Morocco)

Author keywords

Autoantibodies; Diagnosis; Prognosis; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CELL NUCLEUS ANTIGEN; DNA BINDING PROTEIN; DNA DIRECTED RNA POLYMERASE; KU ANTIGEN; SMALL NUCLEAR RIBONUCLEOPROTEIN;

BLOOD; CENTROMERE; HUMAN; IMMUNOLOGY; PROGNOSIS; REVIEW; SYSTEMIC SCLEROSIS;

ANTIBODIES, ANTINUCLEAR; ANTIGENS, NUCLEAR; AUTOANTIBODIES; CENTROMERE; DNA-BINDING PROTEINS; DNA-DIRECTED RNA POLYMERASES; HUMANS; PROGNOSIS; RIBONUCLEOPROTEIN, U1 SMALL NUCLEAR; SCLERODERMA, SYSTEMIC;

EID: 70149088527     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2009.0332     Document Type: Article

References (41)

1. Takehara K, Sato S. Localised scleroderma is an autoimmune disorder. Rheumatology 2005; 44 : 274-9.
2. Derk CT, Jimenez SA. Systemic sclerosis : current views of its pathogenesis. Autoimmunity Revi 2003; 2 : 181-91.
3. Tager RE, Tikly M. Clinical and laboratory manifestations of systemic sclerosis in Black South Africans. Rheumatology 1999; 38 : 397-400.
4. Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths D. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology 2004; 43 : 596-602.
5. Mayes MD, Lacey Jr. JV, Dimmer JB, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48 : 2246-55.
6. Sohail SA, Filemon TK. Identification of novel targets in scleroderma : update on population studies, cDNA arrays, SNP analysis, and mutations. Curr Opin Rheumatol 2003 : 766-71.
7. Genth E, Mierau R. Diagnostic significance of scleroderma and myositis-associated autoantibodies. Z Rheum 1995; 54 : 39-49.
8. Mouthon L, Garcia De la pena-Lefebvre P, Chanseaud Y, Tamby MC, Boissier MC, Guillevin L. Pathogénie de la sclérodermie systémique : aspects immunologiques. Ann Med Int 2002; 153 : 167-78.
9. Steen V. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35 : 35-42.
10. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003; 5 : 80-93.
11. Hachulla E, Dubucquoi S. Intérêt des anticorps antinucléaires pour le diagnostic, la classification et le pronostic de la sclérodermie systémique. Rev Med Int 2004; 25 : 442-7.
12. Francès C, Ayoub N, Barete S. Comment reconnaÎtre une sclérodermie. Les sclérodermies. Rev Prat 2002; 52 : 1884-90.
13. Meyer O. Du syndrome de Thibierge-Weissenbach (1910) aux anticorps anti-centromère (1980). De la clinique à la biologie. Ann Med Int 1999; 150 : 47-52.
14. Carpentier PH. Acrosyndromes sclérodermiques. Rev Prat 2002; 52 : 1891-5.
15. Harris ML, Rosen A. Autoimmunity in scleroderma : the origin, pathogenic role and clinical significance of autoantibodies. Curr Opin Rheum 2003; 15 : 778-84.
16. Meyer O. Syndrome CREST. Ann Med Int 2002; 153 : 183-8.
17. Sato S, Hamaguchi Y, Hasegawa M, Takehara K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology 2001; 40 : 1135-40.
18. Diot E, Yalat C, Boissinot E, Giraudeau B, Asquier E, Guilmot JL, et al. Stratégie pour le diagnostic précoce de l'atteinte pulmonaire dans la sclérodermie systémique. Rev Mal Resp 2000; 17 : 1073-80.
19. Miller MH, Littlejohn GO, Davidson A, Jones B, Topliss DJ. The clinical significance of the anticentromere antibody. Brit Rheum 1989; 8 : 231-7.
20. Fabien N, Rousset H. Diagnostic immunologique des sclérodermies. Pathol Biol 2002; 50 : 243-55.
21. Yalaoui S, Gorgi Y, Ayed K. Comparaison de trois techniques pour la recherche des anticorps anti-Scl 70. Ann Biol Clin (Paris) 2001; 59 : 639-42.
22. Huong Du Le T, Sauvaget F, Johanet C, De Gennes C, Raguin G, Abuaf N, et al. Anticorps Anti-Scl70 dans la sclérodermie systémique. Ann Dermatol Venereol 1990; 117 : 103-7.
23. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Brit Rheum 1998; 37 : 15-20.
24. Humbel RL. Anticorps anti-nucléaires et anti-cytoplasmiques. In : Humbel RL, ed. Autoanticorps et maladies autoimmunes. Paris : Elsevier, 1997 : 91.
25. Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 1999; 117 : 395-402.
26. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Åkesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 2003; 42 : 534-40.
27. Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 2001; 40 : 1157-62.
28. Yang JM, Hildebrandt B, Luderschmidt C, Pollard KM. Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar RNP complex. Arthritis Rheum 2003; 48 : 210-7.
29. Brouwer R, Vree Egberts W, Hengstman G, Raijmakers R, van Engelen B, Seelig Hans P, et al. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 2002; 4 : 134-8.
30. Jablonska S, Blaszczyk M, Jarzabek-Chorzelska M, Chorzelski T, Kolacinska-Strasz Z. Immunological markers of the subsets of systemic scleroderma and its overlap. Arch Immunol Ther Exp (Warsz) 1991; 39 : 381-90.
31. Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Sato S, et al. Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol 1999; 117 : 383-7. (Pubitemid 29343614)
32. Laraki R, Bletry O. Sclérodermie systémique. In : Godeau P, Herson S, Piette JC, eds. Traité de médecine interne. Paris : Médecine-sciences Flammarion, 1996 : 131-6.
33. Yamane K, Ihn H, Kubo M, Kuwana M, Asano Y, Yazawa N, et al. Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma. Rheumatology 2001; 40 : 683-6.
34. Ulanet DB, Wigley FM, Gelber AC, Rosen A. Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. Arthitis Rheum 2003; 15 : 85-92.
35. Marrakchi H, Fazaa B, Gorgi Y, Jellouli A, Mokhtar I, Kamoun MR. Anticorps anti-phospholipides et sclérodermie systémique, à propos d'un cas avec revue de la littérature. Tunisie Med 1995; 73 : 149-52.
36. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37 : 75-83.
37. Boffa JJ, Rossert J. Atteintes rénales sclérodermiques. Rev Prat 2002; 52 : 1910-4.
38. Armadans CP, Fonollosa LV, Solans R, Selva A, Villar M, Lima J, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 2003; 42 : 71-5.
39. Bizzaro N, Tonutti E, Villalta D, Basseti D, Tozzoli R, Manoni F, et al. Sensitivity and Specificity of I mmunological methods for detection of Anti-Topoisomerase I (Scl70) autoantibodies : results of a Multicenter Study. Clin Chem 2000; 46 : 1681-5.
40. Buitrago-González JM, González C, Hernando M, Carrasco R, Sánchez A, Navajoand W, et al. Antibodies to centromere antigens measured by an automated enzyme immunoassay. Clin Chim Acta 2003; 28 : 135-8.
41. Bizzaro N, Tozzoli R, Tonutti E, Piazza A, Manoni F, Ghirardello A, et al. Variability between methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies : a collaborative study with the biomedical industry. J Immunol Methods 1998; 219 : 99-107.